Wantstats
Company ProfilePremium

Bavarian Nordic

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Bavarian Nordic - Healthcare showcase

Year Founded & Workforce

1992

1,000 Employees

Industry

Healthcare

Services

Biodefense Market
B

Bavarian Nordic Employee Contacts

38 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Bavarian Nordic Overview

Company Headquarters: Denmark, Europe

Founded: 1992

Workforce: ~1000

Company Working: Bavarian Nordic is a fully integrated vaccines company focused on R&D innovation, vaccine manufacturing, and vaccine commercialization. It has built a commercial infrastructure with a presence in key countries in Europe and the US in order to drive profitable expansion of its expanding vaccine portfolio. The company is an expert in the production of live viral vaccines, and the fill & finish capabilities has enabled end-to-end commercial-scale production

Strategy

Bavarian Nordic unveiled a five-year strategy in 2020. Building on its core strengths in vaccine research, development, and manufacturing, it accelerated its growth through a strategic product acquisition and organizational expansion to include a full, global commercial infrastructure, transforming itself into a full-fledged vaccine company with the goal of becoming one of the largest pure play vaccine companies by 2025, with annual revenues exceeding USD 1 billion

Company Snapshot

$319.66M

Revenue

1,000

Employees

1992

Founded

Denmark, Europe

Headquarters

SWOT Analysis

Strengths

  • Sate of the art research and development facility
  • High customer satisfaction
  • Strategic acquisitions

Weaknesses

  • High dependency on developed markets
  • Earnings growth is expected to be slow

Opportunities

  • Increase R&D expenditure to drive innovations
  • Expansion into new market after government agreement

Threats

  • New technological developments by a few competitors within the industry pose a threat to the company
  • Fluctuations in foreign currency rates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
May 2023–Bavarian Nordic announced the completion of its acquisition of Emergent BioSolutions Inc.'s (US) travel vaccination portfolio.
December 2022–Bavarian Nordic announced a new agreement with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) for the advanced development of MVA-BN WEV, a prophylactic vaccine candidate against Western, Eastern, and Venezuelan equine encephalitis virus.
November 2022–Bavarian Nordic announced the signing of a cooperative procurement agreement with HERA, the European Commission's Health Emergency Preparedness and Response Authority, for the provision of up to 2 million doses of its MVA-BN monkeypox vaccine in 2023 and 2024.
October 2022–Bavarian Nordic announced that the Swiss Federal Office of Public Health and the Swiss Armed Forces had ordered 100,000 doses of MVA-BN smallpox and monkeypox vaccine.
October 2022–Bavarian Nordic announced a supply arrangement with a Latin American country for their monkeypox vaccine.
July 2022–Bavarian Nordic announced that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by vaccinia virus.

Product Offering

  • Bavarian Nordic
    • Biodefense Market

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →